A biomarker analysis of plasma and tumor DNA in afatinib-treatedpatients with EGFR mutation-positive advanced adenocarcinoma of the lung. - Afatinib I I S

Clinical Research Support Center Kyushu0 个研究点目标入组 30 人开始时间: 2014年5月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with active double cancer 2)Patients with interstitial pneumonia confirmed by chest CT. 3)Patient with neurologic symptom caused by non-treated brain metastasis 4) Patients with either superior vena cava syndrome, pericardial effusion, pleural effusion or ascites >= Grade 3. 5) Patients with an operation with the systemic anesthesia within 28 days before enrollment. 6)Patient with a palliative radiotherapy for the metastatic focus except the chest (including gamma knife treatment for the brain metastatic focus) within 7 days before enrollment (the irradiation of the same day 2 weeks ago is permitted as enrollment day as day0). 7) Patient with a radiation exposure to the chest or mediastinum within 14 days before enrollment (the irradiation of the same day 2 weeks ago is permitted as enrollment day as day0). 8)Patients with complication with mental disease or a mind symptom, and are judged to have difficulty in participation in the study. 9) Patient with positive HBs antigen. 10) Patient having a serious infection to need systemic treatment. 11)Any other patients who are regarded as unsuitable for this study by the investigators.

发起方

Clinical Research Support Center Kyushu